Home Sitemap
Home > Publications and Presentations

Publications and Presentations

publications_and_presentations_2.html

The publications and presentations are arranged by the year of publication. Please choose from the years below to view the publications and presentations for that year

2015 2014  2013 2012  2011   2010  2009  2008   2007  2006  2005  2004  2003 2002  2001   2000  1999




2015

Publications
  1. Jarrin I, Pantazis N, Dalmau J, Phillips AN, Olson A, Mussini C, Boufassa F, Costagliola D, Porter K, Blanco J, Del Amo J, Martinez-Picado J for CASCADE Collaboration in EuroCoord. Does rapid HIV disease progression prior to cART hinder optimal CD4+ T-cell recovery once HIV-1 suppression is achieved? AIDS 2015. In press.
  2. Simmons R, Malyuta R, Chentsova N, Medoeva A, Kruglov Y, Yurchenko A, Copas A, Porter K, for CASCADE Collaboration in EuroCoord. HIV Testing and Diagnosis Rates in Kiev, Ukraine: April 2013 - March 2014. PLoS One. 2015 Aug 31;10:e0137062. doi: 10.1371/journal.pone.0137062 [Article]
  3. Rosiñska M, Simmon R, Marzec-Boguslawska A, Janiec J, Porter K. Relating HIV testing patterns in Poland to risky and protective behaviour. AIDS Care 2015. In press.
  4. Pantazis N, Touloumi G, Meyer L, Olson A, Cotagliola D, Kelleher AD, Lutsar I, Chaix M-L, Fisher M, Moreno S, Porter K for CASCADE Collaboration in EuroCoord. The impact of transient cART in early HIV infection on viral suppression and immunologic response in later treatment. AIDS 2015. In press.
Conference presentations
  1. Jarrin I, Dalmau J, Pantazis N, Olson A, Mussini C, Phillips A, Boufassa F, Costagliola, Porter K, Blanco J, del Amo J, Marinez-Picado J. Rapid progression hinders the recovery of CD4+ T Cells following initiation of cART. 22nd Conference on Retroviruses and Opportunistic Infections, 23-26 February 2015, Seattle, US. [Poster]
  2. Mangal TD. Joint Estimation of HIV Progression and Mortality Among HIV Seroconverters including the CASCADE Collaboration in EuroCoord. 22nd Conference on Retroviruses and Opportunistic Infections, 23-26 February 2015, Seattle, US. [Webcast]
  3. Simmons R, Malyuta R, Chentsova C, Karnets I, Murphy G, Duong Y, Dobbs T, Medoeva A, Kruglov Y, Yurchenko A, Copas A, Porter K. HIV incidence estimates, introducing the Limiting Antigen Avidity EIA to existing HIV surveillance in Kiev City, Urkaine: 2013-2014. 22nd Conference on Retroviruses and Opportunistic Infections, 23-26 February 2015, Seattle, US. [Poster]
  4. Olson A, Sabin C, Prins M, Meyer L, del Amo J, Chene G, Hamouda O, Touloumi G, Porter K. Is survival following HIV seroconversion still improving, 17 years after the introduction of cART? 22nd Conference on Retroviruses and Opportunistic Infections, 23-26 February 2015, Seattle, US. [Poster]
  5. Olson A, Kucherer C, Sonnerborg A, de Mendoza C, Zangerle R, Prins M, Gill J, Bakken Kran AM, Paraskevis D, Porter K. Temporal trends of transmitted HIV drug resistance following seroconversion. 22nd Conference on Retroviruses and Opportunistic Infections, 23-26 February 2015, Seattle, US. [Poster]
  6. Fearnhill EL, Gourlay A, Malyuta R, Ferns B, Nastouli E, Simmons R, Karnets I, Murphy G, Medoeva A, Kruglov Y, Paraskevis D, Yurchenko A, Porter K. Transmission Clustering among Kiev Sequences. 15th European AIDS Conference, 21-24 October 2015, Barcelona, Spain.
  7. Paraskevis D, Beloukas A, Stasinos K, Pantazis N, de Mendoza C, Kucherer C, Ratman O, Bezemer D, Zangerle R, Gill J, d'Arminio Montforte A, Bakken Kran A-M, Porter K. HIV-1 Local Transmission Networks in 9 European Countries and Canada: Association with Demographic and Clinical Factors.15th European AIDS Conference, 21-24 October 2015, Barcelona, Spain.
  8. Van Santen DK, Prins M. No Decline in Hepatitis C (HCV) Incidence among HIV-positive Men who Have Sex with Men (MSM) within CASCADE: 1990-2014. 15th European AIDS Conference, 21-24 October 2015, Barcelona, Spain.
  9. Lyons A, Costagliola D, Mussini C, Zangerle R, d'Arminio Monforte A, Sannes M, Meyer L, Gill J, Porter K, Sabin C, Ford D. Is HIV infection duration associated with myocardial infarctions?15th European AIDS Conference, 21-24 October 2015, Barcelona, Spain.


2014

Publications
  1. Olson A, Meyer L, Prins M, Thiebaut R, Gurdasani D, Guiguet M, Chaix ML, Amornkul P, Babiker A, Sandhu MS and Porter K for CASCADE Collaboration in EuroCoord. An Evaluation of HIV Elite Controller Definitions within a Large Seroconverter Cohort Collaboration. PLoS ONE. 2014 Jan 28;9:e86719. doi: 10.1371/journal.pone.0086719 [Article]
  2. Simmons R, Semeneko I, Tolpina M, Tereschenko R, Kotlik L, Zasyptka L, Murphy G, McKinney E, Copas A, Malyuta R, Porter K. High percentage of recent HIV infection leading to onward transmission in Odessa, Ukraine associated with young adults. AIDS Behav 2014;18:411-8. [PubMed]
  3. Boufassa F, Lechenadec J, Meyer L, Costagliola D, Hunt PW, Pereyra F, Deeks S, Pancino G, Taulera O, Lichterfeld M, Delobel P, Saez-Cirion A, Lambotte O; ANRS CO18 HIV Controllers Cohort; Cascade Collaboration in Eurocoord; SCOPE Cohort; International HIV Controllers Study. Blunted response to combination antiretroviral therapy in HIV elite controllers: an international HIV controller collaboration. PLoS One. 2014 Jan 17;9:e85516. [Article]
  4. Olson A, Guiguet M, Zangerle R, Gill J, Perez-Hoyos S, Lodi S, Ghosn J, Dorrucci M, Johnson A, Sannes M, Moreno S, Porter K; for CASCADE Collaboration in EuroCoord. Evaluation of rapid progressors in HIV infection as an extreme phenotype. J Acquir Immune Defic Syndr 2014;67:15-21. [Article]
  5. Pantazis N, Porter K, Costagliola D, De Luca A, Ghosn J, Guiguet M, Johnson A, Kelleher A, Morrison C, Thiebaut R, Wittkop L, Touloumi G, for the CASCADE Collaboration in EuroCoord. Temporal trends in prognostic markers of HIV-1 virulence and transmissibility. An observational cohort study. Lancet HIV 2014; doi:10.1016/S2352-3018(14)00002-2. [Abstract] [PDF and Appendix].
  6. Van der Helm J, Geskus R, Lodi S, Meyer L, Schuitemaker H, Gunsenheimer-Bartmeyer B, d'Arminio Monforte A, Olson A, Touloumi G, Sabin C, Porter K, Prins M; on behalf of CASCADE Collaboration in EuroCoord. Characterisation of long-term non-progression of HIV-1 infection after seroconversion: a cohort study. The Lancet HIV 2014;1:e41-e48. doi: 10.1016/S2352-3018(14)70016-5  [Abstract]
Conference presentations
  1. Fidler S, Olson A, Fox J, Phillips A, Morrison C, Thornhill J, Bucher H, Muga R, Porter K. The importance of viral blips and duration of therapy initiated in primary infection in maintaining viral control after stopping cART. Presented at the 2014 HIV Drug Therapy Glasgow Meeting, 2-6 November 2014, Glasgow, Scotland. Poster #P288 [Abstract].
  2. Pantazis N, Porter K, Costagliola D, De Luca A, Ghosn J, Guiguet M, Kelleher A, Morrsion C, Thiebaut R, Touloumi G, on behalf of the CASCADE Collaboration in EuroCoord. Temporal Trends in Prognostic Markers of HIV-1 Virulence and Transmissibility. Presented at the 21st Conference on Retroviruses and Opportunistic Infections, 3-6 March 2014, Boston, US. [Webcast]
  3. An der Heiden M, Zoufaly A, Sabin C, van Lunzen J, Stelbrink H, Gunsenheimer-Bartmeyer B, Vanhems P, Perez-Hoyos S, Chene G, Hamouda O, on behalf of the CASCADE Collaboration in EuroCoord. The Clinical Impact of Viral Load Copy Years in Antiretroviral-Naive HIV Seroconverters. Presented at the 21st Conference on Retroviruses and Opportunistic Infections, 3-6 March 2014, Boston, US. [Abstract 291]
  4. Olson A, Walker S, Suthar A, Sabin C, Bucher H, Jarrin I, Moreno S, Perez-Hoyos S, Porter K, Ford D, on behalf of the CASCADE Collaboration in EuroCoord. Value of Viremia Copy Years in Deciding Optimal Timing of ART Initiation in Adults with HIV. Presented at the 21st Conference on Retroviruses and Opportunistic Infections, 3-6 March 2014, Boston, US. [Abstract 558]



2013

Publications

  1. Lodi S, Fisher M, Phillips A, De Luca A, Ghosn J, Malyuta R, Zangerle R, Moreno S, Vanhems P, Boufassa F, Guiguet M, Porter Kholoud, for CASCADE Collaboration in EuroCoord. Symptomatic Illness and Low CD4 Cell Count at HIV Seroconversion as Markers of Severe Primary HIV Infection. PLoS ONE 2013;8:e78642. [Article]
  2. Touloumi G, Pantazis N, Chaix ML, Bucher H C, Zangerle R, Bakken Kran AM, Thiebaut R, Masquelier B, Kucherer C, d’Arminio Monforte A, Meyer L and Porter K for CASCADE Collaboration in EuroCoord. Virologic and immunologic response to cART by HIV-1 subtype in the CASCADE Collaboration. PLoS ONE 2013; 8:e71174. [Article]
  3. Madec Y, Boufassa F, Porter K, Prins M, Sabin C, d’Arminio Monforte A, Amornkul P, Bartmeyer B, Sannes M, Venet A, Lambotte O and Meyer L on behalf of the CASCADE Collaboration in Eurocoord. Natural History of HIV control since seroconversion: experience from the CASCADE collaboration. AIDS 2013; 24;27:2451-60. [PubMed]
  4. Pantazis N, Kenward MG, Touloumi G on behalf of CASCADE Collaboration in EuroCoord. Performance of parametric survival models under non-random interval censoring: a simulation study. Computational Statistics and Data Analysis 2013;63,16-30.[Abstract]
  5. Van der Helm J, Geskus R, Sabin C, Meyer L, del Amo J, Chêne G, Dorrucci M, Muga R, Porter K, Prins M on behalf of CASCADE collaboration in EuroCoord. Effect of HCV infection on cause-specific mortality following HIV seroconversion before and after 1997. Gastroenterology 2013;144:751-760. [PubMed]
  6. Rosiñska M, Marzec-Boguslawska A, Janiec J, Smolen-Dzirba J, Wasik T, Gniewosz J, Zalewska M, Murphy G, McKinney E, Porter K for the CASCADE Collaboration in EuroCoord. High percentage of recent HIV infection among HIV-positive individuals newly-diagnosed at voluntary counselling and testing sites in Poland in 2006. AIDS Res Hum Retroviruses 2013;29:805-13. [Article]
  7. Touloumi G, Pantazis N, Pillay D, Paraskevis D, Chaix M L, Bucher H, Kücherer C, Zangerle R, Bakken Kran A M, Porter K, on behalf of the CASCADE collaboration in EuroCoord. Impact of HIV-1 subtype on CD4 count at HIV seroconversion, rate of decline and viral load set point in European seroconverter cohorts.CID 2013;56:888-97. [PubMed]
  8. Lodi S, del Amo J, d’Arminio Monforte A, Abgrall S, Sabin C, Morrison C, Furrer H, Muga R, Porter K, Girardi E on behalf of the CASCADE collaboration in EuroCoord. Risk of tuberculosis following HIV seroconversion in high-income countries. Thorax 2013;68:207-13. [PubMed]
  9. Huang X, Lodi S , Fox Z, Li W, Phillips A, Porter K, Lutsar I, Kelleher A, Li A,  Xu X, Wu H and Johnson A on behalf of the CASCADE collaboration in EuroCoord. Rate of CD4 decline and HIV-RNA change following HIV Seroconversion in men who have sex with men: a comparison between the Beijing PRIMO and CASCADE cohorts. JAIDS 2013;68:207-13. [PubMed]
  10. Smoleñ-Dzirba J, Rosiñska M, Kruszyñski P, Bratosiewicz-W¹sik J, Janiec J, Beniowski M, Boci¹ga-Jasik M, Jab³onowska E, Szetela B, W¹sik TJ. Transmission of drug-resistant HIV-1 variants among individuals with recent infection in southern Poland. Curr HIV Res. 2013 Jun;11:288-94. [PubMed]

Conference presentations
  1. Olson A, Touloumi G, Geskus R, Meyer L, Prins M, Chêne G, De Luca A, Costagliola D, and Porter K for CASCADE Collaboration in EuroCoord. Mean asymptomatic viral load, steady state viral load and CD4 cell count following acute infection as predictors of HIV disease progression.20th Conference on Retroviruses and Opportunistic Infections, 3-6 March 2013, Atlanta, US. [Abstract]




2012

Publications

  1. Smoleñ-Dzirba J, Rosiñska M, Kruszyñski P, Bratosiewicz-Wasik J, Janiec J, Beniowski M, Bociaga-Jasik M, Jablonowska E, Szetela B, Porter K, Wasik T, and the CASCADE collaboration in EuroCoord. Molecular epidemiology of recent HIV-1 infections in southern Poland. J Med Virol 2012;84:1857-68. [PubMed]
  2. Zugna D, Geskus RB, de Stavola B, Rosinska M, Bartmeyer B, Boufassa F, Chaix M, Babiker A and Porter K for the CASCADE Collaboration in EuroCoord. Differences in time to virological failure, treatment change and interruption, between persons treated within 12 months of HIV seroconversion and in chronic infection. Antivir Ther 2012;17:1039-1048. [PubMed]
  3. Bakoyannis G, Touloumi G. Practical methods for competing risks data: A review. Stat Methods Med Res 2012; 21: 257-72. [PubMed]
  4. Lodi S, Meyer L, Kelleher A, Rosiñska M, Ghosn J, Sannes M, Porter K for the CASCADE Collaboration in EuroCoord. Immuno-virological control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion. Arch Intern Med 2012;172:1252-5. [PubMed]
  5. Pantazis N, Morrison C, Amornkul PN, Lewden C, Salata RA, Minga A, Chipato T, Jaffe H, Lakhi S, Karita E, Porter K, Meyer L, Touloumi G on behalf of CASCADE Collaboration in EuroCoord and ANRS 1220 Primo-CI Study Group. Differences in HIV natural history among African and non-African seroconverters in Europe and seroconverters in sub-Saharan Africa. PLoS ONE 2012;7(3):e32369. [PLoS ONE]
  6. Jarrin I, Pantazis N, Gill J, Geskus R, Perez-Hoyos S, Meyer L, Prins M, Touloumi G, Johnson A, Hamouda O, García de Olalla P, Porter K, del Amo J; CASCADE Collaboration in EuroCoord. Uptake of combination antiretroviral therapy (cART) and HIV disease progression according to geographical origin in seroconverters in Europe, Canada, and Australia. Clin Infec Dis 2012;54:111-118. [PubMed]

Conference presentations

  1. Pantazis N, Kenward M, Touloumi G on behalf of CASCADE Collaboration in EuroCoord. Performance of parametric survival models under non-random interval censoring: a simulation study. 33rd Conference of the International Society for Clinical Biostatistics, 19-23 August 2012, Bergen, Norway. [Abstract]
  2. Bakoyannis G. Late entry bias in cohort studies with competing endpoints. 33rd Conference of the International Society for Clinical Biostatistics, 19-23 August 2012, Bergen, Norway. [Abstract]
  3. Smith R, Semenenko I, Tolpina M, Tereschenko R, Kotlik L, Zasyptka L, Murphy G, McKinney E, Malyuta R, Porter K on behalf of CASCADE Collaboration in EuroCoord. High percentage of recent HIV infection leading to onward transmission in Odessa, Ukraine associated with young adults.19th International AIDS Conference, 22-27 July 2012, Washington DC, US. [Abstract]
  4. Olson A, Meyer L, Prins M, Thiebaut R, Guiguet M, Chaix ML, Amornkul P, Babiker A and Porter K for CASCADE Collaboration in EuroCoord. Proportion of HIV elite controllers and loss of elite status according to two commonly used definitions. 19th Conference on Retroviruses and Opportunistic Infections, 5-8 March 2012, Seattle, US. [Abstract]
  5. Lodi S, Fisher M, Phillips A, De Luca A, Ghosn J, Malyuta R, Zangerle R, Moreno S, Porter K for CASCADE Collaboration in EuroCoord. Identification of severe primary HIV infection through clinical, immunological and virological definitions. 19th Conference on Retroviruses and Opportunistic Infections, 5-8 March 2012, Seattle, US. [Abstract]
  6. Van der Helm J on behalf of the CASCADE collaboration. Effect of hepatitis C coinfection on cause-specific mortality following HIV seroconversion in the pre-cART and cART eras. 47th annual meeting of the European Association for the Study of Liver (EASL), 18-22 April 2012, Barcelona, Spain. [Abstract]





2011

Publications
  1. Funk MJ, Fusco J, Cole S, Davidian M, Thomas J, Kaufman J, White A, Hartmann K, Porter K, Eron J. Timing of HAART initiation and clinical outcomes HIV-1 seroconverters. Arch Intern Med 2011;171:1560-9. [PubMed]
  2. Lodi S, Phillips A, Touloumi G, Geskus R, Meyer L, Thiébaut R, Pantazis N, del Amo J, Johnson A M, Babiker A, Porter K on behalf of the CASCADE Collaboration in EuroCoord. Time from HIV seroconversion to reaching CD4 thresholds <200, <350 and <500 cells/mm3; assessment of need following changes in treatment guidelines. Clin Infec Dis 2011;53:817-825. [PubMed]
  3. Mussini C, Cossarizza A, Sabin C, Babiker A, De Luca A, Heiner A, Bucher C, Fisher M, Rezza G, Porter K, Dorrucci M. Decline of CD4+ T cell count before start of therapy and immunological response to treatment in antiretroviral-naïve individuals. AIDS 2011; 15;25:1041-1049 [PubMed]
  4. Van der Helm J, Prins M, Del Amo J, Bucher HC, Chêne G, Dorrucci M, Gill MJ, Hamouda O, Sannes M, Porter K, Geskus RB; on behalf of the CASCADE collaboration. The Hepatitis C epidemic among HIV-positive men who have sex with men: incidence estimates from 1990 to 2007. AIDS 2011; 15;25:1083-1091  [PubMed] 
  5. Jaffe H, De Stavola B, Carpenter L, Porter K and Cox D. Immune reconstitution and risk of Kaposi sarcoma and non-Hodgkin lymphoma in HIV-infected adults. AIDS 2011; 25:1395-1403. [Pubmed]
  6. Wittkop L, Günthard H, de Wolf F, Dunn D, Cozzi-Lepri A, de Luca A, Kücherer C, Obel N, von Wyl V, Masquelier B, Stephan C, Torti C, Antinori A, García F, Judd A, Porter K, Thiébaut R, Castro H, van Sighem AI, Colin C, Kjaer J, Lundgren JD, Paredes R, Pozniak A, Clotet B, Phillips A, Pillay D, Chêne G, for the EuroCoord-CHAIN study group. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis 2011;11:363-371 [Pubmed] 
     

Conference presentations

  1. Lodi S,  d’Arminio Monforte A, del Amo J, Abgrall S, Sabin C, Porter K, Girardi E. Risk of tuberculosis following HIV seroconversion in low-burden tuberculosis countries. 17-20 July 2011,IAS, Rome, Italy [Abstract]
  2. Huang X, Lodi S, Fox Z, Phillips A, Johnson A, Porter K, Xu X and Wu H on behalf of the Beijin PRIMO cohort study and the CASCADE collaboration. Patterns of decrease in CD4 cell count after seroconversion: Comparison between Beijing PRIMO cohort and CASCADE seroconverter cohorts. 17-20 July 2011, IAS, Rome, Italy [Abstract]
  3. Van der Helm J, Prins M, del Amo J, Bucher H C, Chêne G, Dorrucci M, Gill M J, Hamouda O, Sannes M, Porter K, Geskus R B, on behalf of the CASCADE collaboration. The Hepatitis C epidemic among HIV-positive men who have sex with men: incidence estimates from 1990 to 2007. International Liver Congress EASL,30March- 3 April, 2011, Berlin, Germany [Abstract]
  4. Touloumi G, Pantazis N, Chaix M L, Meyer L, Thiébaut R, Masquelier B, Kücherer C, d’Arminio Monforte A, Lodi S, Porter K, and CASCADE. Virologic and immunologic response to cART by HIV-1 subtype in the CASCADE Collaboration. 18th Conference on Retroviruses and Opportunistic Infections, February 2011, Boston, USA.






2010

Publications

  1. Bakoyannis G, Siannis F, Touloumi G. Modelling competing risks data with missing cause of failure. Stat Med 2010; 29:3172-85 [PubMed]
  2. Drylewicz J, Guedj J, Commeneges D, Thiébaut R. Modeling the dynamics of biomarkers during primary HIV infection taking into account the uncertainty of infection date. Ann. Appl Stat 2010:4; 1847-1870 [link]
  3. Bucher HC, Wolbers M, Porter K. 2010 guidelines for antiretroviral treatment of HIV from the International AIDS Society-USA Panel (letter to the Editor). JAMA 2010;304:1897 [PubMed]
  4. Lodi S, Phillips A, Touloumi G, Pantazis N, Bucher HC, Babiker A, Chêne G, V Philippe, Porter K. CD4 decline in seroconverter and seroprevalent patients in the pre-cART era. AIDS 2010;24:2697-2704[PubMed]
  5. Lodi S, Guiguet M, Costagliola D, Fisher M, de Luca A, Porter K and the CASCADE Collaboration. Incidence of Kaposi's Sarcoma and survival following its diagnosis in HIV-infected homosexual men followed up since HIV seroconversion. J Natl Cancer Inst. 102:784-92 [PubMed]
  6. Wolbers M, Babiker A, Sabin C, Dorrucci M, Chêne G, Mussini C, Porter K, Bucher HC, on behalf of the CASCADE Collaboration. Pre-treatment CD4 cell slope and progression to AIDS or death in naïve HIV-infected patients initiating combination antiretroviral therapy: The CASCADE Collaboration. PLoS Med. 2010 23;7:e1000239[Pubmed].

Conference presentations

  1. Lodi S, Kücherer, Bakken Kran AM, Masquelier B, d'Arminio Monforte A, Gill J, Dunn D, Pillay D, Porter K on behalf of the CASCADE Collaboration. Long-term probability of detecting drug-resistant HIV in patients starting antiretroviral therapy within the first year of HIV infection. Tenth International Congress on Drug Therapy in HIV Infection, 7-11 November, Glasgow, UK (oral presentation). [Abstract]
  2. Wolbers M, Babiker A, Porter K, Bucher HC, on behalf of the CASCADE Collaboration. CD4 cell slope and AIDS - a case study in longitudinal data analysis and prediction. ISCB 2010, 29 August - 2 September Montpellier, France
  3. Funk M, Fusco JS, Cole SR, Thomas JC, Porter K, Kaufman JS, Davidian M, White AD, Hartmann KE, Eron JJ, CASCADE Collaboration. HAART initiation and clinical outcomes: insights from the CASCADE cohort of HIV-1 serovonverters on 'When to Start'. XVIII International AIDS Conference, 18-23 July 2010, Vienna, Austria. [Abstract]
  4. Madec Y, Boufassa F, Prins M, Sabin C, d'Arminio A, Amournkul P, Venet A, Lambotte O, Porter K, Meyer L on behalf of the CASCADE Collaboration. HIV controllers with a known date of seroconversion - What happens before and during HIV control? XVIII International AIDS Conference, 18-23 July 2010, Vienna, Austria. [Abstract]
  5. van der Helm J, Geskus R, Sabin C, Meyer L, del Amo J, Muga R, Porter K, Prins M. The effect of HCV co-infection on cause-specific mortality. XVIII International AIDS Conference, 18-23 July 2010, Vienna, Austria. [Abstract]
  6. van der Helm J, Jansen I, Porter K, Geskus R, Lodi S, Meyer L, Sabin C, Schuitemaker H, Gunsenheimer-Bartmeyer B, d'Arminio Montforte A, Prins M, on behalf of the CASCADE Collaboration. The characterisation of long-term non-progression of HIV-1 infection since seroconversion. XVIII International AIDS Conference, 18-23 July 2010, Vienna, Austria. [Abstract]
  7. van der Wal WM, Prins M, del Amo J, Perez-Hoyos S, Porter K, Geskus RB, Urbanus A. Trends in the causal effect of AIDS defining conditions on mortality. XVIII International AIDS Conference, 18-23 July 2010, Vienna, Austria. [Abstract]
  8. Jarrin I, Gill J, Geskus R, Meyer L, Touloumi G, Prins M, Hamouda O, Pantazis N, Perez-Hoyos S, Porter K, del Amo J, and the CASCADE Collaboration. Differences in time from HIV seroconversion to HAART initiation according to geographical origin. XVIII International AIDS Conference, 18-23 July 2010, Vienna, Austria. [Abstract]
  9. Lodi S, Phillips A, Touloumi G, Geskus R, Meyer L, Thiebaut R, Pantazis N, del Amo J, Babiker A, Porter K, on behalf of the CASCADE Collaboration. Proportion of individuals likely to need treatment for CD4 thresholds <200, <350, and <500 cells. The 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 2010. [Poster]
  10. Lodi S, Murphy G, Rosinska M, Smolen J, Zalewska M, Janiec J, Marzec-Boguslawska, Porter K. Concordance of recent HIV infection between three STARHS assays is not dependent on patient characteristics. The 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 2010. [Poster]
  11. Pantazis N. Longitudinal CD4 cell count evolution during HIV natural history: comparison between European and sub-Saharan African seroconverter cohorts.The 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 2010. [Poster]
  12. Jarrin I, Gill J, Geskus R, Meyer L, Touloumi G, Prins M, Hamouda O, Perez-Hoyos S, Porter K, del Amo J. Differences in time to AIDS and death following HIV seroconversion according to geographical origin.The 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 2010. [Poster]
  13. van der Helm J, Geskus R, del Amo J, Chêne G, Gill J, Hamouda O, Sannes M, Porter K, Prins M, on behalf of the CASCADE Collaboration. The hepatitis C epidemic among HIV-positive men who have sex with men started before 2000. The 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 2010. [Poster]




2009

Publications

  1. Marin B, Thiébaut R, Bucher HC, Rondeau V, Costagliola D, Dorrucci M, Hamouda O, Prins M, Walker AS, Porter K, Sabin CA, Chêne G on behalf of the CASCADE Collaboration. Non-AIDS defining deaths and immunodeficiency in the era of combination antiretroviral therapy. CASCADE 1996-2006. AIDS 2009: 23; 1743-53 [PubMed]
  2. Brown AE, Gifford RJ, Clewley JP, Kucherer C, Masquelier B, Porter K, Balotta C, Back NK, Jorgensen LB, de Mendoza C, Bhaskaran K, Gill ON, Johnson AM, Pillay D on behalf of the CASCADE Collaboration. Phylogenetic reconstruction of transmission events from individuals with acute HIV infection: toward more rigorous epidemiological definitions. JID 2009; 199:427-431 [PubMed]

Conference presentations
  1. van der Helm J, Geskus RB, del Amo J, Porter K, Prins M on behalf of CASCADE Collaboration. The hepatitis C epidemic among HIV-positive men who have sex with men started before 2000. Accepted as a poster presentation at the 18th International Society for STD Research Conference, 28th June - 1st July 2009, London. 
  2. Lodi S, Porter K, Phillips A, on behalf of the CASCADE Collaboration. Time to reaching CD4≤500 for individuals followed up since HIV seroconversion. Accepted as a poster to the 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, July 19th-22nd July 2009, Cape Town. [Abstract]
  3. Ewings F, Walker AS, Porter K, Copas A. Using causal models to determine optimal dynamic treatment regimes with a time-to-event outcome. Accepted as an oral presentation at the 30th Annual Conference of the International Society for Clinical Biostatistics, 23rd - 27th August 2009, Prague. Abstract reference: S11.4. [Abstract]
  4. van der Wal W, del Amo-Valero J, Porter K, Perez-Hoyos S, Prins M, Geskus RB, on behalf of the CASCADE Collaboration. Causal effect of AIDS-defining conditions on mortality modified by HAART use and calendar time. Accepted as an oral presentation at the 30th Annual Conference of the International Society for Clinical Biostatistics, 23rd - 27th August 2009, Prague. Abstract reference S27.3. [Abstract]
  5. Drylewicz J, Walker S, Commenges D, Pillay D, Venet A, Masquelier B, Meyer L, Chêne G, Porter K, Thiébaut R, and the CASCADE Collaboration. Plasma HIV RNA and CD4+ count dynamics during acute infection in 761 HIV-1-infected patients: The CASCADE Collaboration. The 16th Conference on Retroviruses and Opportunistic Infections, Montreal, February 2009 [Abstract]

2008

Publications

  1. Pantazis N, Touloumi G, Vanhems P, Gill J, Bucher H, Porter K on behalf of the CASCADE Collaboration. The effect of antiretroviral treatment of different durations in primary HIV infection. AIDS 2008; 22:2441-50 [PubMed]
  2. Touloumi G, Pantazis N, Stirnadel AH, Walker AS, Boufassa F, Vanhems P, Porter K on behalf of the CASCADE Collaboration. Rates and determinants of virologic and immunologic response to HAART resumption after treatment interruption in HIV-1 clinical practice. JAIDS. 2008;49:492-8. [PubMed]
  3. Bhaskaran K, Hamouda O, Sannes M, Boufassa F, Johnson A, Lambert P and Porter K on behalf of the CASCADE Collaboration. Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA 2008; 2;300:51-9 [PubMed]
  4. Jarrin I, Geskus R, Bhaskaran K, Prins M, Perez-Hoyos S, Muga R, Hernández-Aguado I, Meyer L, Porter K, del Amo J and CASCADE. Gender differences in HIV progression to AIDS and Death in industrialised countries: Slower disease progression following HIV seroconversion in women. AJE 2008; 168:532-40 [PubMed]
  5. The Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study. Response to combination antiretroviral therapy (cART): variation by age. AIDS 2008;22:1463-73 [PubMed]
  6. Bhaskaran K, Mussini C, Antinori A, Walker AS , Dorrucci M, Sabin C, Phillips A, Porter K on behalf of CASCADE Collaboration. Changes in the incidence and predictors of HIV-associated dementia in the era of highly active antiretroviral therapy. Ann Neurol. 2008;63:213-21 [PubMed]
  7. Guiguet M, Porter K, Phillips A, Costagliola D, Babiker A on behalf of the CASCADE collaboration. Clinical progression rates by CD4 cell category before and after the initiation of combination antiretroviral therapy (cART). Open AIDS Journal 2008;2:3-9 [pdf]
  8. Dunn DT, Woodburn P, Duong T, Peto J, Phillips A, Gibb D, Porter K on behalf of HIV Paediatric Prognostic Markers Collaborative Study (HPPMCS) and the CASCADE Collaboration. Current CD4 cell count and the short-term risk of AIDS and death before the availability of effective antiretroviral therapy in HIV-infected children and adults. J Infect Dis 2008; 197:398-404. [PubMed]

Conference Presentations

  1. Pantazis N, Touloumi G, Vanhems P, Gill J, Porter K. The effect of antiretroviral treatment of different durations in primary HIV infection. 15th Conference on Retroviruses and Opportunistic Infections, Boston, February 2008. [Poster]
  2. Porter K, Hamouda O, Sannes M, Boufassa F, Johnson A, Walker S. Changes over time in the risk of death following HIV seroconversion compared with mortality in the general population. 15th Conference on Retroviruses and Opportunistic Infections, Boston, February 2008. [Abstract] [Presentation] 

[back to top]


2007

Publications

  1. Dorrucci M, Rezza G, Porter K, Phillips A and Concerted Action on Seroconversion to AIDS and Death in Europe Collaboration. Temporal trends in post-seroconversion CD4 cell count and HIV load: the Concerted Action on Seroconversion to AIDS and Death in Europe Collaboration, 1985-2002. J Infect Dis 2007; 195:525-34.[PubMed]
  2. Lampe FC, Porter K, Kaldor J, Law M, Kinloch-de Loes S, Phillips AN on behalf of the CASCADE Collaboration. Effect of transient antiretroviral treatment during acute HIV infection: comparison of the Quest trial results with CASCADE natural history study. Antivir Ther 2007; 12:189-93.[PubMed]
  3. Fidler S, Fox J, Touloumi G, Pantazis N, Porter K, Babiker A, Weber J and the CASCADE Collaboration. Slower CD4 cell decline following cessation of a 3-month course of HAART in primary HIV infection. AIDS. 2007 Jun 19; 21:1283-91.[PubMed]

Conference Presentations

  1. Marin B, Thiébaut R, Rondeau V, Costagliola D, Dorrucci M, Bucher H, Hamouda O, Walker AS, Bhaskaran K, Chêne G on behalf of the CASCADE Collaboration. Association between CD4 and HIV RNA with non AIDS-related causes of death in the era of combination Antiretroviral Therapy (cART). 4th IAS Conference on HIV Pathogenesis and Treatment, Sydney July 2007 [WEPEB019].[Abstract]
  2. Touloumi G, Pantazis N, Stirnadel HA, Walker AS, Boufassa F, Vanhems P, Porter K on behalf of the CASCADE Collaboration. Determinants of immunological response to HAART resumption after treatment interruption in HIV-1 clinical practice. 4th IAS Conference on HIV Pathogenesis and Treatment, Sydney July 2007 [WEPEB072]. [Abstract]
  3. Porter K, Bhaskaran K on behalf of CASCADE Collaboration. Continuing improvements in survival in the era of HAART. 4th IAS Conference on HIV Pathogenesis and Treatment, Sydney July 2007 [TUPEB093]. [Abstract]
  4. Brown AE, Gifford RJ, Porter K, Clewley JP, Gill ON, Johnson AM, Pillay D on behalf of the CASCADE Collaboration. A phylogenetic exploration of the role of seroconverters in transmitting HIV drug resistant viruses within Europe. 14th International Workshop on HIV Dynamics & Evolution, Parador De Segovia, Spain April 2007 [53].
  5. Dunn D, Woodburn P, Duong T, Phillips A, Gibb D, Porter K on behalf of HIV Paediatric Prognostic Markers Collaborative Study (HPPMCS) and the Concerted Action on SeroConversion to AIDS and Death in Europe (CASCADE Collaboration). A comparison of the rate of clinical disease progression in HIV-infected children and adults allowing for current CD4 cell count. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, February 2007 [700]. [Poster]
  6. Fidler S, Touloumi G, Fox J, Pantazis N, Porter K, Babiker A,Weber J on behalf of the CASCADE Collaboration. Slower CD4 cell decline following cessation of a 3-month course of HAART in Primary HIV infection. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, February 2007 [348]. [Poster]
  7. Jarrín I, Del Amo J, Bhaskaran K, Pérez-Hoyos S, Hernández-Aguado I, Meyer L, Prins M, Porter K on behalf of the CASCADE Collaboration. Changes over time in the risk of AIDS by sex: slower progression in women in recent periods. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, February 2007 [776]. [Poster]

[back to top]



2006

Publications

  1. Touloumi G, Pantazis N, Antoniou A, Stirnadel AH, Walker AS, Porter K on behalf of the CASCADE Collaboration. HAART interruption: predictors and virologic and immunologic consequences. JAIDS 2006; 42:554-561. [PubMed]
  2. Smit C, Geskus R, Walker S, Sabin C, Coutinho R, Porter K, Prins M on behalf of the CASCADE Collaboration. Effective therapy has altered the spectrum of cause specific mortality following HIV seroconversion. AIDS 2006; 20:741-9. [PubMed]
  3. Bezemer D, de Ronde A, Prins M, Porter K, Gifford R, Pillay D, Masquelier B, Fleury H, Dabis F, Back N,  Jurriaans S, van der Hoek L on behalf of the CASCADE Collaboration. Transmission of HIV-1 with drug resistance mutations that evolve in the absence of antiviral therapy results in a mild initial decline of CD4 cell counts. Antivir Ther 2006; 11:173-8. [PubMed]
  4. Pillay D, Bhaskaran K, Jurriaans S, Prins M, Masquelier B, Dabis F, Gifford R, Nielsen C, Pedersen C, Balotta C, Rezza G, Ortiz M, de Mendoza C, Kücherer C, Poggensee G, Gill J, Porter K on behalf of the CASCADE Virology Collaboration. The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy. AIDS 2006; 20:21-8. [PubMed]
  5. Thiébaut R, Jacqmin-Gadda H, Walker S, Sabin C, Prins M, Del Amo J, Porter K, Dabis F, Chêne G on behalf of the CASCADE Collaboration. Determinants of response to first HAART regimen in antiretroviral-naive patients with an estimated time since HIV seroconversion. HIV Medicine 2006; 7:1-9. [PubMed]

Conference Presentations

  1. Touloumi G, Paraskevis D, Pantazis N, Pillay D, Masquelier B, Kucherer C, Magiorkinis E, Porter K, Hatzakis A on behalf of the CASCADE Collaboration. Effect of HIV-1 recombinant subtypes on disease progression in European seroconverters. XVI International AIDS Conference Toronto, August 2006 [TUPE0018]. [Abstract]
  2. Touloumi G, Pantazis N, Stirnadel HA, Walker AS, Porter K on behalf of the CASCADE Collaboration. Rates and predictors of virologic and immunologic response to therapy resumption after treatment interruption in HIV-1 clinical practice. XVI International AIDS Conference Toronto, August 2006 [THPE0148]. [Abstract]
  3. Mussini C, Bhaskaran K, Walker S, Dorrucci M, Sabin C, Phillips A, Porter K on behalf of the CASCADE Collaboration. The Predictors of HIV Encephalopathy and Outcome in HIV+ Patients in the Era of Effective Therapy. 13th Conference on Retroviruses and Opportunistic Infections, Denver, February 2006 [351]. [Poster]

[back to top]



2005

Publications

  1. Masquelier B, Bhaskaran K, Pillay D, Gifford R, Balestre E, Bruun Jørgensen L, Pedersen C, van der Hoek L, Prins M, Balotta C, Longo B, Kücherer C, Poggensee G, Ortiz M, del Romero J, Gill J, Fleury H, Porter K on behalf of the CASCADE Collaboration. Prevalence and factors associated with transmitted HIV drug resistance: the role of patient characteristics and different interpretation algorithms. JAIDS 2005; 40:505-11. [PubMed]
  2. Madec Y, Boufassa F, Porter K and Meyer L on behalf of the CASCADE Collaboration. Spontaneous control of viral load and CD4 progression among HIV-1 seroconverters in CASCADE. AIDS 2005; 19:2001-7. [PubMed]
  3. Pantazis N, Touloumi G, Walker AS, Babiker A on behalf of the CASCADE Collaboration. Bivariate modelling of longitudinal measurements of two HIV-1 disease progression markers in the presence of informative drop-outs. Appl Statist 2005; 54:405-23.
  4. Thiébaut R, Jacqmin-Gadda H, Babiker A, Commenges D on behalf of the CASCADE Collaboration. Joint modelling of bivariate longitudinal data with informative drop out and left censoring, with application to the evolution of CD4+ cell count and HIV RNA viral load in response to treatment of HIV infection. Stat Med 2005; 24:65-82. [PubMed]
  5. May M, Porter K, Sterne J, Royston P, Egger M. Prognostic model for HIV-1 disease progression in patients starting antiretroviral therapy was validated using independent data. J Clin Epi 2005; 58:1033-41. [PubMed]

Conference Presentations

  1. Porter K, Bhaskaran K on behalf of the CASCADE Collaboration. Times to reaching undetectable viral load and rebound for persons treated during primary and chronic HIV infection. 3rd IAS Conference on HIV Pathogenesis and Treatment, Rio de Janeiro July 2005 [WePe12.1C01]. [Abstract]
  2. Bhaskaran K on behalf of the CASCADE Collaboration. The difficulties of investigating the role of HCV coinfection on survival and response to HAART. 3rd IAS Conference on HIV Pathogenesis and Treatment, Rio de Janeiro July 2005 [TuPe1.1C13] [Abstract]
  3. Touloumi G, Pantazis N and Porter K on behalf of the CASCADE Collaboration. Long-term virological and immunological effects of HAART initiated in the first 12 months after HIV-1 seroconversion. 3rd IAS Conference on HIV Pathogenesis and Treatment, Rio de Janeiro, July 2005 [WePe12.1CO2]. [Abstract]
  4. Bezemer D, de Ronde A, Prins M, Porter K, Pillay D, Masquelier B, Dabis F, Back N, Jurriaans S, van der Hoek L on behalf of the CASCADE Collaboration. Transmission of HIV-1 with drug-resistance mutations that evolve in the absence of ART results in a mild initial decline of CD4 cell counts. 12th Conference on Retroviruses and Opportunistic Infections, Boston, February 2005 [630]. [Abstract]

[back to top]



2004

Publications

  1. Touloumi G, Pantazis N, Babiker AG, Walker AS,Katsarou O, Karafoulidou A, Hatzakis A, Porter K on behalf of the CASCADE Collaboration. Differences in HIV-RNA levels before the initiation of antiretroviral therapy among 1864 individuals with known HIV-1 seroconversion dates. AIDS 2004; 18:1697-1705. [PubMed]
  2. Bhaskaran K, Brettle R, Porter K, Walker AS on behalf of the CASCADE Collaboration. Systemic non-Hodgkin lymphoma in persons with known dates of HIV seroconversion: incidence and predictors. AIDS 2004; 18:673-81. [PubMed]
  3. Phillips A on behalf of the CASCADE Collaboration. Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naive individuals and those treated in the monotherapy era. AIDS 2004; 18:51-8. [PubMed]
  4. Collaboration of HIV Cohorts. Pre- and within-HAART nucleoside analogue use and viral load rebound on HAART. JID 2004; 190:675-87. [PubMed]
  5. The PLATO Collaboration. Predictors of CD4 count trend and mortality among HIV-1-infected persons with virologic failure to all three antiretroviral drug classes. Lancet 2004; 364:51-62. [PubMed]

Conference Presentations

  1. Thiébaut R, Jacqmin-Gadda H, Dabis F, Chêne G pour la Collaboration CASCADE. Déterminants de la réponse viro-immunologique au premier traitement antirétroviral chez des patients naïfs dont le délai depuis la date d'infection par le VIH peut être estimé. Congrès ADELF (Association des Epidémiologistes de Langue Française), Bordeaux, September 2004.
  2. Pillay D on behalf of the CASCADE Collaboration. Initial CD4 decline following seroconversion is determined by infection with drug resistant HIV-1. XV International AIDS Conference Bangkok, July 2004. [WePeB5752]. [Abstract]
  3. Bhaskaran K on behalf of the CASCADE Collaboration. Variation in the determinants of developing specific AIDS events. XV International AIDS Conference Bangkok, July 2004. [TuPeC4724]. [Abstract]
  4. Thiébaut R on behalf of the CASCADE Collaboration. Determinants of response to first HAART regimen in naive patients adjusting for HIV infection duration. XV International AIDS Conference Bangkok, July 2004. [TuPeB4545]. [Abstract]
  5. Porter K on behalf of the CASCADE Collaboration. Determinants of CD4 normalisation for individuals presenting with CD4 <350 cells/ml at seroconversion. XV International AIDS Conference Bangkok, July 2004. [MoPeC3370]. [Abstract]
  6. Gifford R, Cane P, Back N, Fleury H, Nielsen C,Ortiz M, Balotta C, Porter K, Pillay D on behalf of the CASCADE Virology Collaboration. Phylogenetic relationships between HIV-1 viruses from seroconverters across Europe. 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 2004 [391]. [Poster]
  7. Pillay D, Jurriaans S, Prins M, Masquelier B, Dabis F, Nielsen C, Pedersen C, de Mendoza C, Belda J, Balotta C, Rezza G, Gifford R, Porter K on behalf of the CASCADE Virology Collaboration. The impact of transmitted drug resistance on virological response to HAART regimens adjusted for genotypic resistance at baseline. 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 2004 [685]. [Abstract]
  8. Masquelier B, Pillay D, van der Hoek L, Prins M, Balestre E, Nielsen C, Pedersen C, del Romero J, Ortiz M, Balotta C, Rezza G, Gifford R, Porter K on behalf of the CASCADE Virology Collaboration. Changes in prevalence and characteristics of transmitted resistance over time amongst european seroconverter cohorts. 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 2004 [683]. [Abstract]

[back to top]



2003

Publications

  1. CASCADE Collaboration. Differences in CD4 cell counts at seroconversion and decline among 5739 HIV-1 infected individuals with known dates of seroconversion. JAIDS 2003; 34:76-83. [PubMed]
  2. CASCADE Collaboration. Determinants of survival following HIV seroconversion after the introduction of HAART. Lancet 2003; 362:1267-74. [PubMed]
  3. CASCADE Collaboration. Estimating the effect of antiretroviral treatment during HIV-seroconversion: impact of confounding in observational data. HIV Medicine 2003; 4:332-37. [PubMed]
  4. CASCADE Collaboration. Impact of tuberculosis on HIV disease progression in persons with well documented time of HIV seroconversion. JAIDS 2003; 33:184-190. [PubMed]
  5. CASCADE Collaboration. Short-term CD4 cell response following HAART initiation at different times from seroconversion in 1500 seroconverters. JAIDS 2003; 32:303-10. [PubMed]

Conference Presentations

  1. Touloumi G, Pantazis N, Hatzakis A, Katsarou O, Karafoulidou A, Porter K, Babiker AG on behalf of the CASCADE Collaboration. Differences in HIV-RNA levels during treatment free period of HIV-1 infection among 1864 individuals with known dates of seroconversion. 9th European Conference on Clinical Aspects and Treatment of HIV Infection, October 2003, Warsaw.
  2. Bhaskaran K on behalf of the CASCADE Collaboration. Differences in time to treatment change by class of initial regimen. 9th European Conference on Clinical Aspects and Treatment of HIV Infection, October 2003, Warsaw.
  3. Jonsson Funk M on behalf of the CASCADE Collaboration. Predictors Of CD4 at HAART initiation. 2nd IAS Conference on HIV Pathogenesis and Treatment, Paris 2003 [567]. [Abstract]

[back to top]




2002

Publications

  1. CASCADE Collaboration. Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks. Int J Epi 2002; 31:951-8.  [PubMed]

Conference Presentations

  1. Bhaskaran K on behalf of CASCADE collaboration. Incidence and Predictors of non-Hodgkin lymphoma in European cohorts of HIV seroconverters. Sixth International Congress on drug therapy in HIV infection, Glasgow 2002 [PL7.4].
  2. Porter K, Walker AS on behalf of the CASCADE Collaboration. Factors predicting the uptake of HAART in primary HIV infection (PHI). XIV International AIDS Conference, Barcelona 2002 [ThPeB7196]. [Abstract]
  3. Walker AS on behalf of the CASCADE Collaboration. Factors predicting uptake of HAART at varying CD4 levels. XIV International AIDS Conference, Barcelona 2002 [TuPeB4666]. [Abstract]
  4. Sabin CA on behalf of the CASCADE Collaboration. Short-term immunological response in pre-treated and naive subjects initiating HAART at different times following seroconversion. XIV International AIDS Conference, Barcelona 2002 [TuPeB4667]. [Abstract]
  5. Phillips A and Pezzotti P on behalf of the CASCADE Collaboration. Short term risk of AIDS by current CD4, viral load and age in naïve individuals and those treated in the monotherapy era. XIV International AIDS Conference, Barcelona 2002 [TuPeC4709]. [Abstract]

[back to top]




2001

Publications

  1. Babiker AG, Peto T, Porter K, Walker AS, Darbyshire JH. Age as a determinant of survival in HIV infection. J Clin Epi 2001; S16-21. [PubMed]
  2. CASCADE Collaboration. Is the time from HIV seroconversion a determinant of the risk of AIDS after adjustment for updated CD4 cell counts? JAIDS 2001; 28:158-65. [PubMed]
  3. CASCADE Collaboration. The relationships between the HIV test interval, demographic factors and HIV disease progression. Epidem & Infect 2001; 127:91-100. [PubMed]

Conference Presentations

  1. Bhaskaran K on behalf of the CASCADE Collaboration. Changes in factors associated with HIV survival in a European cohort of seroconverters. 8th Annual meeting of the British HIV Association, York, April 2001 [O2].
  2. Touloumi G, Pantazis N, Hatzakis A, Porter K, Babiker AG on behalf of CASCADE Collaboration. Differences in immunologic progression among 7060 HIV-1 infected individuals with known dates of seroconversion. Eighth European Conference on Clinical Aspects and Treatment of HIV infection, Athens 2001.
  3. Porter K on behalf of the CASCADE collaboration. Changes in HIV survival in a European cohort of persons with well estimated dates of seroconversion. Joint conference of the International Epidemiological Association and the Society for Social Medicine, Oxford 2001.
  4. Porter K on behalf of the CASCADE collaboration Meta-analyses: Magic and Run of the Mill. 7th Annual meeting of the British HIV Association, Brighton, April 2001 [P1].
  5. Walker S on behalf of the CASCADE collaboration CD4 cell response following HAART initiated at different times from HIV seroconversion 7th Annual meeting of the British HIV Association, Brighton, April 2001 [O1].

[back to top]



2000

Publications

  1. CASCADE Collaboration. Effect of ignoring the time of HIV seroconversion in estimating changes in survival over calendar time in observational studies: results from CASCADE. AIDS 2000; 14:1899-1906. [PubMed]
  2. CASCADE Collaboration. Changes in the uptake of antiretroviral therapy and survival in persons with known duration of HIV infection in Europe. HIV Medicine 2000; 1:224-31. [PubMed]
  3. CASCADE Collaboration. Survival after introduction of HAART in people with known duration of HIV infection. Lancet 2000; 355:1158-9. [PubMed]
  4. Collaborative Group on AIDS Incubation and HIV Survival. Time from HIV-1 seroconversion to AIDS and death before the widespread use of highly active anti-retroviral therapy: a collaborative re-analysis. Lancet 2000; 355:1131-7. [PubMed]
  5. International Collaboration on HIV and Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst 2000; 92:1823-30. [PubMed]

Conference Presentations

  1. Walker AS, Babiker AG. Impact of knowledge of the time of infection on the evaluation of secular trends in survival. 21st meeting of the International Society for Clinical Biostatistics, Trento 2000.
  2. De Angelis D, Myles J, Porter K. Parametric models for the distribution of AIDS incubation before widespread use of highly-active antiretroviral therapy. 21st meeting of the International Society for Clinical Biostatistics, Trento 2000 .
  3. J Del Amo, S Perez-Hoyos, M Diez, J Castilla, I Hernandez-Aguado, K Porter. Impact of tuberculosis in HIV disease progression in persons with well documented times of HIV seroconversion. XIII International AIDS Conference, Durban 2000 [WePeC4427].
  4. Pezzotti P, Walker S, Bugarini R on behalf of CASCADE collaboration. The effect of calendar year at risk on time from seroconversion to specific first AIDS events. XIII International AIDS Conference, Durban 2000 [TuPeC3327].
  5. Babiker A, Pezzotti P, Walker S on behalf of CASCADE collaboration. Factors associated with time from seroconversion to all AIDS events. XIII International AIDS Conference, Durban 2000 [TuPeC3325].
  6. Babiker A, Pezzotti P, Walker S on behalf of CASCADE collaboration. Evaluation of the effect of time from seroconversion on AIDS. XIII International AIDS Conference, Durban 2000 [TuOrC367].
  7. Porter K on behalf of CASCADE collaboration. Knowledge of the time of HIV seroconversion is necessary for unbiased estimates of survival. XIII International AIDS Conference, Durban 2000 [TuOrC369].

[back to top]



1999

Publications

  1. None available

Conference Presentations

  1. Porter K on behalf of CASCADE collaboration. Survival estimates in 1997- 1998 from a large cohort of persons with known duration of HIV infection: results from CASCADE (Concerted Action on SeroConversion to AIDS and Death in Europe). Seventh European Conference on Clinical Aspects and Treatment of HIV infection, Lisbon 1999 [416].
  2. Porter K on behalf of CASCADE collaboration. Changes in survival and time to initiating ART in HIV seroconverters in Europe: results from CASCADE (Concerted Action on SeroConversion to AIDS and Death in Europe). Seventh European Conference on Clinical Aspects and Treatment of HIV infection, Lisbon 1999 [246].

[back to top]